Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
UBS
Farmers Insurance
Teva
Express Scripts

Generated: June 18, 2019

DrugPatentWatch Database Preview

OMBITASVIR; PARITAPREVIR; RITONAVIR - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ombitasvir; paritaprevir; ritonavir and what is the scope of ombitasvir; paritaprevir; ritonavir patent protection?

Ombitasvir; paritaprevir; ritonavir is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ombitasvir; paritaprevir; ritonavir has four hundred patent family members in forty-seven countries.

One supplier is listed for this compound.

Summary for OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patents and Regulatory Information for OMBITASVIR; PARITAPREVIR; RITONAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for OMBITASVIR; PARITAPREVIR; RITONAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for OMBITASVIR; PARITAPREVIR; RITONAVIR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2692346 PA2017033,C2692346 Lithuania ➤ Try a Free Trial PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2368890 122015000039 Germany ➤ Try a Free Trial PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115
2368890 C20150016 00154 Estonia ➤ Try a Free Trial PRODUCT NAME: OMBITASVIIR;REG NO/DATE: EU/1/14/982 19.01.2015
2368890 CA 2015 00015 Denmark ➤ Try a Free Trial PRODUCT NAME: OMBITASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/982 20150115
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Accenture
QuintilesIMS
Federal Trade Commission
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.